Nanotechnology - A Financial Perspective from Zurich

Zurich Financial Services Group focuses on Nanotechnology in its latest issue of Industry Insight, its online consumer magazine. It defines nanotechnology as the methods of manipulating atoms and molecules to create new structures at scales measured in billionths of a metre. This issue of Industry Insight provides an overview of nanotechnology today – its enormous commercial potential, the unique risk challenges nanotechnology poses, the regulatory environment for nanotechnology, and a look at what Zurich is doing to help its customers understand and manage the potential risk.

Decoding Humans – Where Are We Now?

Stem Cells Technology and NPOs in Drug Discovery

In the current economic gloom, it is very tempting to write another run-of-the-mill article about how the credit crisis is affecting the pharmaceutical industry and the healthcare domain as a whole. However, since those issues have been covered and belabored threadbare in most other journals, this article will focus on some of the other interesting things that are happening in the industry.

The European HIV/AIDS Market – an Outlook

Europe is the second largest market for HIV/AIDS therapeutics after the US market. However, it is also a very challenging market for pharmaceutical manufacturers because of the differences in policies across the region. The European HIV/AIDS market poses unique challenges to the manufacturers as well as the public health authorities.

The Past, Present and Future of the European Drug Discovery

Increasing costs, a limited drug pipeline and the impeding loss of patent coverage for ‘blockbuster’ drugs are changing the landscape of pharmaceutical science. Certain business strategies will need to be employed to overcome these challenges.

Bio-IT and Biotechnology Outlook for 2009

President-elect Barack Obama Announces His Science and Technology Team

President-elect Barack Obama Announcing his new Science and Technology team.

Diagnostics - Its crucial time

In-vitro diagnostics is in the midst of a major change. Last year, the IVD industry was the centre of media attention as it witnessed one of the largest industry consolidations within the healthcare sector. The entry of medical technology giant Siemens and the aspirations of GE to enter this market, have heightened this interest, as the IVD industry is traditionally considered a low-profit business in the life sciences space.

IBM Reveals Five Innovations That Will Change Our Lives in the Next Five Years

Breast MRI: Will it Lead to an End in Surgeries?

Future of Stem Cell Therapeutics- The Global Scenario.

Life Cycle Management Strategies

Clinical Decision Support Systems

Increasing M&A Activity in the Generics Industry: What happens next?

Insight into the European PCR market

Several procedures such as culture techniques, Immunoassays/Serology and Fluorescent In Situ Hybridisation (FISH) have been used to detect disease agents for many years. However amplification technologies such as polymerase chain reaction (PCR) have been shown to be very popular amongst end users and are creating a great amount of interest in the market place.